Literature DB >> 25724123

The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency.

Karin R Engelhardt1, Michael E Gertz2, Sevgi Keles3, Alejandro A Schäffer2, Elena C Sigmund4, Cristina Glocker4, Shiva Saghafi5, Zahra Pourpak5, Ruben Ceja6, Atfa Sassi7, Laura E Graham8, Michel J Massaad9, Fethi Mellouli10, Imen Ben-Mustapha7, Monia Khemiri11, Sara Sebnem Kilic12, Amos Etzioni13, Alexandra F Freeman14, Jens Thiel4, Ilka Schulze4, Waleed Al-Herz15, Ayse Metin16, Özden Sanal17, Ilhan Tezcan17, Mehdi Yeganeh18, Tim Niehues19, Gregor Dueckers19, Sebastian Weinspach20, Turkan Patiroglu21, Ekrem Unal22, Majed Dasouki23, Mustafa Yilmaz24, Ferah Genel25, Caner Aytekin26, Necil Kutukculer27, Ayper Somer28, Mehmet Kilic29, Ismail Reisli30, Yildiz Camcioglu31, Andrew R Gennery32, Andrew J Cant32, Alison Jones33, Bobby H Gaspar33, Peter D Arkwright34, Maria C Pietrogrande35, Zeina Baz36, Salem Al-Tamemi37, Vassilios Lougaris38, Gerard Lefranc39, Andre Megarbane40, Jeannette Boutros41, Nermeen Galal41, Mohamed Bejaoui10, Mohamed-Ridha Barbouche7, Raif S Geha9, Talal A Chatila6, Bodo Grimbacher42.   

Abstract

BACKGROUND: Mutations in dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency (CID) also classified as autosomal recessive (AR) hyper-IgE syndrome (HIES). Recognizing patients with CID/HIES is of clinical importance because of the difference in prognosis and management.
OBJECTIVES: We sought to define the clinical features that distinguish DOCK8 deficiency from other forms of HIES and CIDs, study the mutational spectrum of DOCK8 deficiency, and report on the frequency of specific clinical findings.
METHODS: Eighty-two patients from 60 families with CID and the phenotype of AR-HIES with (64 patients) and without (18 patients) DOCK8 mutations were studied. Support vector machines were used to compare clinical data from 35 patients with DOCK8 deficiency with those from 10 patients with AR-HIES without a DOCK8 mutation and 64 patients with signal transducer and activator of transcription 3 (STAT3) mutations.
RESULTS: DOCK8-deficient patients had median IgE levels of 5201 IU, high eosinophil levels of usually at least 800/μL (92% of patients), and low IgM levels (62%). About 20% of patients were lymphopenic, mainly because of low CD4(+) and CD8(+) T-cell counts. Fewer than half of the patients tested produced normal specific antibody responses to recall antigens. Bacterial (84%), viral (78%), and fungal (70%) infections were frequently observed. Skin abscesses (60%) and allergies (73%) were common clinical problems. In contrast to STAT3 deficiency, there were few pneumatoceles, bone fractures, and teething problems. Mortality was high (34%). A combination of 5 clinical features was helpful in distinguishing patients with DOCK8 mutations from those with STAT3 mutations.
CONCLUSIONS: DOCK8 deficiency is likely in patients with severe viral infections, allergies, and/or low IgM levels who have a diagnosis of HIES plus hypereosinophilia and upper respiratory tract infections in the absence of parenchymal lung abnormalities, retained primary teeth, and minimal trauma fractures.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. All rights reserved.

Entities:  

Keywords:  Molluscum contagiosum; Primary combined immunodeficiency; autosomal recessive hyper-IgE syndrome; dedicator of cytokinesis 8; hyper-IgE syndrome; signal transducer and activator of transcription 3

Mesh:

Substances:

Year:  2015        PMID: 25724123      PMCID: PMC4530066          DOI: 10.1016/j.jaci.2014.12.1945

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  31 in total

1.  Cutaneous manifestations of DOCK8 deficiency syndrome.

Authors:  Emily Y Chu; Alexandra F Freeman; Huie Jing; Edward W Cowen; Joie Davis; Helen C Su; Steven M Holland; Maria L Chanco Turner
Journal:  Arch Dermatol       Date:  2011-09-19

2.  DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration during immune responses.

Authors:  Yosuke Harada; Yoshihiko Tanaka; Masao Terasawa; Markus Pieczyk; Katsuyoshi Habiro; Tomoya Katakai; Kyoko Hanawa-Suetsugu; Mutsuko Kukimoto-Niino; Tomoko Nishizaki; Mikako Shirouzu; Xuefeng Duan; Takehito Uruno; Akihiko Nishikimi; Fumiyuki Sanematsu; Shigeyuki Yokoyama; Jens V Stein; Tatsuo Kinashi; Yoshinori Fukui
Journal:  Blood       Date:  2012-03-28       Impact factor: 22.113

3.  Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait.

Authors:  Waleed Al-Herz; Raj Ragupathy; Michel J Massaad; Raja'a Al-Attiyah; Arti Nanda; Karin R Engelhardt; Bodo Grimbacher; Luigi Notarangelo; Talal Chatila; Raif S Geha
Journal:  Clin Immunol       Date:  2012-03-30       Impact factor: 3.969

4.  Additional diverse findings expand the clinical presentation of DOCK8 deficiency.

Authors:  Ozden Sanal; Huie Jing; Tuba Ozgur; Deniz Ayvaz; Dara M Strauss-Albee; Sibel Ersoy-Evans; Ilhan Tezcan; Gulten Turkkani; Helen F Matthews; Goknur Haliloglu; Aysel Yuce; Bilgehan Yalcin; Ozay Gokoz; Kader K Oguz; Helen C Su
Journal:  J Clin Immunol       Date:  2012-04-04       Impact factor: 8.317

5.  Flow cytometry biomarkers distinguish DOCK8 deficiency from severe atopic dermatitis.

Authors:  Erin Janssen; Erdyni Tsitsikov; Waleed Al-Herz; Gerard Lefranc; Andre Megarbane; Majed Dasouki; Francisco A Bonilla; Talal Chatila; Lynda Schneider; Raif S Geha
Journal:  Clin Immunol       Date:  2013-12-31       Impact factor: 3.969

6.  Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype.

Authors:  Huie Jing; Qian Zhang; Yu Zhang; Brenna J Hill; Christopher G Dove; Erwin W Gelfand; T Prescott Atkinson; Gulbu Uzel; Helen F Matthews; Peter J Mustillo; David B Lewis; Fotini D Kavadas; I Celine Hanson; Ashish R Kumar; Raif S Geha; Daniel C Douek; Steven M Holland; Alexandra F Freeman; Helen C Su
Journal:  J Allergy Clin Immunol       Date:  2014-05-03       Impact factor: 10.793

7.  Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment.

Authors:  Yu Zhang; Xiaomin Yu; Mie Ichikawa; Jonathan J Lyons; Shrimati Datta; Ian T Lamborn; Huie Jing; Emily S Kim; Matthew Biancalana; Lynne A Wolfe; Thomas DiMaggio; Helen F Matthews; Sarah M Kranick; Kelly D Stone; Steven M Holland; Daniel S Reich; Jason D Hughes; Huseyin Mehmet; Joshua McElwee; Alexandra F Freeman; Hudson H Freeze; Helen C Su; Joshua D Milner
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

8.  PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia.

Authors:  Asbjørg Stray-Pedersen; Paul H Backe; Hanne S Sorte; Lars Mørkrid; Niti Y Chokshi; Hans Christian Erichsen; Tomasz Gambin; Katja B P Elgstøen; Magnar Bjørås; Marcin W Wlodarski; Marcus Krüger; Shalini N Jhangiani; Donna M Muzny; Ankita Patel; Kimiyo M Raymond; Ghadir S Sasa; Robert A Krance; Caridad A Martinez; Shirley M Abraham; Carsten Speckmann; Stephan Ehl; Patricia Hall; Lisa R Forbes; Else Merckoll; Jostein Westvik; Gen Nishimura; Cecilie F Rustad; Tore G Abrahamsen; Arild Rønnestad; Liv T Osnes; Torstein Egeland; Olaug K Rødningen; Christine R Beck; Eric A Boerwinkle; Richard A Gibbs; James R Lupski; Jordan S Orange; Ekkehart Lausch; I Celine Hanson
Journal:  Am J Hum Genet       Date:  2014-06-12       Impact factor: 11.025

9.  Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels.

Authors:  Atfa Sassi; Sandra Lazaroski; Gang Wu; Stuart M Haslam; Manfred Fliegauf; Fethi Mellouli; Turkan Patiroglu; Ekrem Unal; Mehmet Akif Ozdemir; Zineb Jouhadi; Khadija Khadir; Leila Ben-Khemis; Meriem Ben-Ali; Imen Ben-Mustapha; Lamia Borchani; Dietmar Pfeifer; Thilo Jakob; Monia Khemiri; A Charlotta Asplund; Manuela O Gustafsson; Karin E Lundin; Elin Falk-Sörqvist; Lotte N Moens; Hatice Eke Gungor; Karin R Engelhardt; Magdalena Dziadzio; Hans Stauss; Bernhard Fleckenstein; Rebecca Meier; Khairunnadiya Prayitno; Andrea Maul-Pavicic; Sandra Schaffer; Mirzokhid Rakhmanov; Philipp Henneke; Helene Kraus; Hermann Eibel; Uwe Kölsch; Sellama Nadifi; Mats Nilsson; Mohamed Bejaoui; Alejandro A Schäffer; C I Edvard Smith; Anne Dell; Mohamed-Ridha Barbouche; Bodo Grimbacher
Journal:  J Allergy Clin Immunol       Date:  2014-04-01       Impact factor: 10.793

10.  DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation.

Authors:  Haifa H Jabara; Douglas R McDonald; Erin Janssen; Michel J Massaad; Narayanaswamy Ramesh; Arturo Borzutzky; Ingrid Rauter; Halli Benson; Lynda Schneider; Sachin Baxi; Mike Recher; Luigi D Notarangelo; Rima Wakim; Ghassan Dbaibo; Majed Dasouki; Waleed Al-Herz; Isil Barlan; Safa Baris; Necil Kutukculer; Hans D Ochs; Alessandro Plebani; Maria Kanariou; Gerard Lefranc; Ismail Reisli; Katherine A Fitzgerald; Douglas Golenbock; John Manis; Sevgi Keles; Reuben Ceja; Talal A Chatila; Raif S Geha
Journal:  Nat Immunol       Date:  2012-05-13       Impact factor: 25.606

View more
  62 in total

Review 1.  Negative Regulation of Type 2 Immunity.

Authors:  Dimitri A de Kouchkovsky; Sourav Ghosh; Carla V Rothlin
Journal:  Trends Immunol       Date:  2017-01-09       Impact factor: 16.687

2.  Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency.

Authors:  Susanne E Aydin; Alexandra F Freeman; Waleed Al-Herz; Hamoud A Al-Mousa; Rand K Arnaout; Roland C Aydin; Vincent Barlogis; Bernd H Belohradsky; Carmem Bonfim; Robbert G Bredius; Julia I Chu; Oana C Ciocarlie; Figen Doğu; Hubert B Gaspar; Raif S Geha; Andrew R Gennery; Fabian Hauck; Abbas Hawwari; Dennis D Hickstein; Manfred Hoenig; Aydan Ikinciogullari; Christoph Klein; Ashish Kumar; Marianne R S Ifversen; Susanne Matthes; Ayse Metin; Benedicte Neven; Sung-Yun Pai; Suhag H Parikh; Capucine Picard; Ellen D Renner; Özden Sanal; Ansgar S Schulz; Friedhelm Schuster; Nirali N Shah; Evan B Shereck; Mary A Slatter; Helen C Su; Joris van Montfrans; Wilhelm Woessmann; John B Ziegler; Michael H Albert
Journal:  J Allergy Clin Immunol Pract       Date:  2018-11-02

3.  Dedicator of cytokinesis 8 regulates signal transducer and activator of transcription 3 activation and promotes TH17 cell differentiation.

Authors:  Sevgi Keles; Louis Marie Charbonnier; Venkataraman Kabaleeswaran; Ismail Reisli; Ferah Genel; Nesrin Gulez; Waleed Al-Herz; Narayanaswamy Ramesh; Antonio Perez-Atayde; Neslihan E Karaca; Necil Kutukculer; Hao Wu; Raif S Geha; Talal A Chatila
Journal:  J Allergy Clin Immunol       Date:  2016-05-24       Impact factor: 10.793

Review 4.  Insights into immunity from clinical and basic science studies of DOCK8 immunodeficiency syndrome.

Authors:  Helen C Su; Huie Jing; Pam Angelus; Alexandra F Freeman
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

5.  Language Impairment with a Partial Duplication of DOCK8.

Authors:  Antonio Benítez-Burraco; Maite Fernández-Urquiza; Mª Salud Jiménez-Romero
Journal:  Mol Syndromol       Date:  2020-12-11

Review 6.  RHO GTPases: from new partners to complex immune syndromes.

Authors:  Rana El Masri; Jérôme Delon
Journal:  Nat Rev Immunol       Date:  2021-02-05       Impact factor: 53.106

Review 7.  DOCK8 regulates signal transduction events to control immunity.

Authors:  Conor J Kearney; Katrina L Randall; Jane Oliaro
Journal:  Cell Mol Immunol       Date:  2017-04-03       Impact factor: 11.530

Review 8.  Human hyper-IgE syndrome: singular or plural?

Authors:  Qian Zhang; Bertrand Boisson; Vivien Béziat; Anne Puel; Jean-Laurent Casanova
Journal:  Mamm Genome       Date:  2018-08-09       Impact factor: 2.957

Review 9.  Quantitative Imaging Approaches to Study the CAR Immunological Synapse.

Authors:  Malini Mukherjee; Emily M Mace; Alexandre F Carisey; Nabil Ahmed; Jordan S Orange
Journal:  Mol Ther       Date:  2017-06-26       Impact factor: 11.454

10.  The clinical and laboratory spectrum of dedicator of cytokinesis 8 immunodeficiency syndrome in patients with a unique mutation.

Authors:  Arnon Broides; Amarilla B Mandola; Jacov Levy; Baruch Yerushalmi; Vered Pinsk; Michal Eldan; George Shubinsky; Nurit Hadad; Rachel Levy; Amit Nahum; Miriam Ben-Harosh; Atar Lev; Amos Simon; Raz Somech
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.